Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Thriemer, Kamala ^a   Ley, Benedikt ^a   Bobogare, Albino ^b   Dysoley, Lek ^c,d   Alam, Mohammad Shafiul ^e   Pasaribu, Ayodhia P ^f   Sattabongkot, Jetsumon ^g   Jambert, Elodie ^h   Domingo, Gonzalo J ⁱ   Commons, Robert ^a   Auburn, Sarah ^a   Marfurt, Jutta ^a   Devine, Angela ^j,k   Aktaruzzaman, Mohammad M ^l   Sohel, Nayeem ^l   Namgay, Rinzin ^m   Drukpa, Tobgyel ^m   Sharma, Surender Nath ⁿ   Sarawati, Elvieda ^o   Samad, Iriani ^o   Theodora, Minerva ^o   Nambanya, Simone ^p   Ounekham, Sonesay ^q   Mudin, Rose Nanti Binti ^q   Da Thakur, Garib ^r   Makita, Leo Sora ^s   Deray, Raffy ^t   Lee, Sang Eun ^u   Boaz, Leonard ^b   Danansuriya, Manjula N ^v   Mudiyanselage, Santha D ^v   Chinanonwait, Nipon ^w   Kitchakarn, Suravadee ^w   Nausien, Johnny ^x   Naket, Esau ^x   Duc, Thang Ngo ^y   Do Manh, Ha ^y   Hong, Young S ^z   Cheng, Qin ^aa   Richards, Jack S ^ab   Kusriastuti, Rita ^ac,ad   Satyagraha, Ari ^ae   Noviyanti, Rintis ^ae   Ding, Xavier C ^af   Khan, Wasif Ali ^e   Swe Phru, Ching ^e   Guoding, Zhu ^ag   Qi, Gao ^ag   Kaneko, Akira ^ah,ai   Miotto, Olivo ^j,aj,ak   Nguitragool, Wang ^al   Roobsoong, Wanlapa ^g   Battle, Katherine ^k   Howes, Rosalind E ^k   Roca Feltrer, Arantxa ^am   Duparc, Stephan ^h   Bhowmick, Ipsita Pal ^an   Kenangalem, Enny ^ao   Bibit, Jo Anne ^ap   Barry, Alyssa ^aq,ar   Sintasath, David ^as   Abeyasinghe, Rabindra ^at   Sibley, Carol H ^au,av   McCarthy, James ^aw   Von Seidlein, Lorenz ^j   Baird, J Kevin ^k,ax   Price, Ric N ^a,k   more..

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Pacific Malaria Initiative Support Centre   (Solomon Islands)

^c National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^d National Institute of Public Health   (Cambodia)

^e International Centre for Diarrheal Diseases and Research   (Bangladesh)

^f UNIVERSITY OF SUMATERA UTARA   (Indonesia)

^g MAHIDOL UNIVERSITY   (Thailand)

^h Medicines for Malaria Venture MMV   (Switzerland)

ⁱ PATH   (United States)

^j MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l MINISTRY OF HEALTH AND FAMILY WELFARE   (Bangladesh)

^m Vector borne Disease Control Programme (VDCP)   (Bhutan)

ⁿ GOVERNMENT OF INDIA   (India)

^o National Malaria Control Program   (Indonesia)

^p National Center for Entomology Parasitology and Malaria Control   (Laos)

^q MINISTRY OF HEALTH   (Malaysia)

^r Minister for Health and Population Nepal   (Nepal)

^s National Malaria Control Programme   (Papua New Guinea)

^t DEPARTMENT OF HEALTH   (Philippines)

^u Korea Centers for Disease Control and Prevention   (South Korea)

^v MINISTRY OF HEALTH   (Sri Lanka)

^w MINISTRY OF PUBLIC HEALTH   (Thailand)

^x National Malaria Control Programme   (Vanuatu)

^y National Institute of Malaria   (Viet Nam)

^z Access Bio Inc   (United States)

^aa AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^ab BURNET INSTITUTE   (Australia)

^ac MINISTRY OF HEALTH   (Indonesia)

^ad Indonesian Medical Association   (Indonesia)

^ae Eijkman Institute of Molecular Biology   (Indonesia)

^af Malaria Fever Program   (Switzerland)

^ag JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^ah KAROLINSKA INSTITUTE   (Sweden)

^ai Osaka Prefecture University   (Japan)

^aj UNIVERSITY OF OXFORD   (United Kingdom)

^ak WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^al MAHIDOL UNIVERSITY   (Thailand)

^am MALARIA CONSORTIUM   (United Kingdom)

^an INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^ao Yayasan Pengembangan Kesehatan dan Masyarakat Papua Timika   (Indonesia)

^ap RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^aq WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^ar UNIVERSITY OF MELBOURNE   (Australia)

^as UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^at WORLD HEALTH ORGANIZATION   (Switzerland)

^au WorldWide Antimalarial Resistance Network   (United Kingdom)

^av UNIVERSITY OF WASHINGTON   (United States)

^aw QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^ax OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

more..

Author keywords

APMEN; P. vivax; Primaquine; Radical cure; Tafenoquine; Vivax malaria

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PRIMAQUINE; TAFENOQUINE; ANTIMALARIAL AGENT;

ARTICLE; BIOSENSOR; BLOOD ANALYSIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HUMAN; LABORATORY TEST; MALARIA RAPID TEST; PATHOGEN CLEARANCE; PATIENT COMPLIANCE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STAFF TRAINING; TREATMENT OUTCOME; ASIA; DIAGNOSTIC TEST; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, VIVAX; PACIFIC ISLANDS; UTILIZATION;

ANTIMALARIALS; ASIA; DIAGNOSTIC TESTS, ROUTINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, VIVAX; PACIFIC ISLANDS;

EID: 85016978562     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1784-1     Document Type: Article

References (57)

1. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36-57.
2. Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007;23:533-9.
3. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti Elyazar I, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg. 2007;77:984-91.
4. RBM. The Asia Pacific Malaria Elimination Network (APMEN) supporting the common goal of a malaria-free Asia Pacific (Progress & impact series, 11). Geneva: Roll Back Malaria Parternship Secreteriat; 2014.
5. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112.
6. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377.
7. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64-74.
8. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
9. WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016. http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/.
10. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Perceptions of P. vivax malaria and barriers to routine G6PD testing prior to its treatment with primaquine. Malar J. 2017. (under review).
11. Vivax Working Group. Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malar J. 2015;14:484.
12. Recht J, Ashley E, White NJ. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014.
13. Monteiro WM, Moura-Neto JP, Recht J, Bassat Q, Lacerda MV. Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A(-) variant in the Brazilian Amazon. Clin Infect Dis. 2016;62:1188.
14. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.
15. Beutler E, Duparc S. G6PD deficiency working group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779-89.
16. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.
17. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135.
18. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430-5.
19. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546-9.
20. Leslie T, Briceno M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, et al. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med. 2010;7:e1000283.
21. IMPROV Study Group. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis. 2015;15:558.
22. Devine A, Parmiter M, Chu C, Bancone G, Nosten F, Price RN et al. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: a cost-effectiveness analysis. PLoS Neglect Trop Dis. Under review. 2017.
23. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, et al. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ. 2007;334:403.
24. Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda P, et al. Improved diagnostic testing and malaria treatment practices in Zambia. JAMA. 2007;297:2227-31.
25. Uzochukwu BS, Onwujekwe E, Ezuma NN, Ezeoke OP, Ajuba MO, Sibeudu FT. Improving rational treatment of malaria: perceptions and influence of RDTs on prescribing behaviour of health workers in southeast Nigeria. PLoS ONE. 2011;6:e14627.
26. Okebe JU, Walther B, Bojang K, Drammeh S, Schellenberg D, Conway DJ, et al. Prescribing practice for malaria following introduction of artemether-lumefantrine in an urban area with declining endemicity in West Africa. Malar J. 2010;9:180.
27. Juma E, Zurovac D. Changes in health workers’ malaria diagnosis and treatment practices in Kenya. Malar J. 2011;10:1.
28. Msellem MI, Martensson A, Rotllant G, Bhattarai A, Stromberg J, Kahigwa E, et al. Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation study. PLoS Med. 2009;6:e1000070.
29. Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS ONE. 2011;6:e18419.
30. Skarbinski J, Ouma PO, Causer LM, Kariuki SK, Barnwell JW, Alaii JA, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg. 2009;80:919-26.
31. Malaria Consortium. Learning Brief-Successful roll out of RDTs in Uganda.
32. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.
33. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049-58.
34. Brito MA, Peixoto HM, Almeida AC, Oliveira MR, Romero GA, Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop. 2016;49:446-55.
35. Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS ONE. 2016;11:e0148172.
36. Henriques G, Raut S, Phommasone K, Adhikari B, Pongvongsa T, Ley B, et al. Prevalence of glucose-6-phosphote dehydrogenase deficiency among a rural and remote population of Lao PDR (Laos). Atlanta: ASTMH Annual Meeting; 2016.
37. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res. 2015;165:677-88.
38. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, et al. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Neglect Trop Dis. 2016;10:e0004457.
39. Ley B, Alam MS, O’Donnell JJ, Hossain MS, Kibria MG, Jahan N, et al. A comparison of three quantitative methods to estimate G6PD activity in the Chittagong Hill tracts, Bangladesh. PLoS ONE. 2017;12:e0169930.
40. Pereira EA, Ishikawa EA, Fontes CJ. Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region. Malar J. 2011;10:355.
41. Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, et al. Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health. 2011;42:9-18.
42. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J. 2010;9:308.
43. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr. 2009;27:4-13.
44. Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg. 2010;82:1017-23.
45. CNM. Meeting report. Meeting on Diagnosis and Treatment in the context of elimination. Phnom Penh: CNM2016.
46. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 2004;98:168-73.
47. Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. PLoS ONE. 2016;11:e0162944.
48. Nsagha DS, Lange I, Fon PN, Nguedia Assob JC, Tanue EA. A randomized controlled trial on the usefulness of mobile text phone messages to improve the quality of care of HIV and AIDS patients in Cameroon. Open AIDS J. 2016;10:93-103.
49. Steury EE. Mobile phone short message service to improve malaria pharmacoadherence in Zambia. J Nurs Scholarsh. 2016;48:354-61.
50. Talisuna AO, Oburu A, Githinji S, Malinga J, Amboko B, Bejon P, et al. Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial. Malar J. 2017;16:46.
51. Liu JX, Modrek S. Evaluation of SMS reminder messages for altering treatment adherence and health seeking perceptions among malaria care-seekers in Nigeria. Health Policy Plan. 2016;31:1374-83.
52. Githinji S, Jones C, Malinga J, Snow RW, Talisuna A, Zurovac D. Development of a text-messaging intervention to improve treatment adherence and post-treatment review of children with uncomplicated malaria in western Kenya. Malar J. 2015;14:320.
53. Haase J, Farris KB, Dorsch MP. Mobile applications to improve medication adherence. Telemed J E Health. 2017;23:75-9.
54. Price RN, Nosten F. Single-dose radical cure of Plasmodium vivax: a step closer. Lancet. 2014;383:1020-1.
55. Travis SF, Kumar SP, Paez PC, Delivoria-Papadopoulos M. Red cell metabolic alterations in postnatal life in term infants: glycolytic enzymes and glucose-6-phosphate dehydrogenase. Pediatr Res. 1980;14:1349-52.
56. Konrad PN, Valentine WN, Paglia DE. Enzymatic activities and glutathione content of erythrocytes in the newborn: comparison with red cells of older normal subjects and those with comparable reticulocytosis. Acta Haematol. 1972;48:193-201.
57. WHO. World Malaria Report. Geneva. Switzerland: World Health Organization; 2015. p. 2015.